Cancer Vaccines Market by Treatment (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), and Indication (Cervical Cancer, Prostate Cancer), Vaccine Type (Recombinant Cancer Vaccine, Dendritic Cells Cancer Vaccine, Whole Cell Cancer Vaccine, Viral Vector and DNA Cancer Vaccine and Antigen/Adjuvant Cancer Vaccine), End User (Adults and Pediatrics) – Market Size & Forecast, 2019-2030
Report ID : 209 | Published Date : Jan 2020 | Pages : 170 | Region : Global | Report Code : PH-13
Cancer Vaccines Market Overview and Introduction
Vaccines are biological products which help the body to fight diseases. These drugs train the immune system of an individual to recognize a foreign antigen and destroy the same in case of any encounter. In majority of cases, cancer cells have certain distinct molecules on its surface, known as cancer-specific antigens. The immune system gets simulated when these cells are introduced in the body of an individual, who has already been administered with a vaccine. Cancer vaccines can majorly be classified into two types, viz. prevention vaccines and treatment or therapeutic vaccines.
Several factors have triggered the need for appropriate vaccines to both prevent and treat cancers. Growing application of Human Papillomavirus (HPV) & hepatitis B vaccines for prevention from cancer-causing viruses, has been one of the most prominent factors contributing to the growth of the global vaccines market. Similarly, rising cases of cancers worldwide has also propelled the need for vaccines to these conditions. Moreover, growing focus on R&D, increasing investments & funding and, supportive government research for cancer treatments and increasing number of clinical trials have been pivotal in augmenting the growth of the global cancer vaccines. However, high cost Involved in vaccine development and high risks and uncertainty involved in vaccine production are few of the factors which may restrain the growth of the market to a certain extent.
The global cancer vaccines market is majorly classified into three segments, viz. by treatment, indication, vaccine type, end user and region.
Cancer Vaccines Market by Treatment
The segment of treatment can be further categorized as, preventive cancer vaccines and therapeutic cancer vaccines.
Cancer Vaccines Market by Indication
On the basis of product, the cancer vaccines market is bifurcated into three segments, i.e., cervical cancer, prostate cancer and other indications
Cancer Vaccines Market by Vaccine Type
On the basis of vaccine type, the cancer vaccines market is bifurcated into the following segments, i.e., recombinant cancer vaccine, dendritic cells cancer vaccine, whole cell cancer vaccine, viral vector and DNA cancer vaccine and antigen/adjuvant cancer vaccine.
Cancer Vaccines Market by End User
On the basis of end user, cancer vaccines market has be classified into adults, and pediatrics. The pediatric segment is expected to account for the largest share in the global cancer vaccines market. The large share of this segment can be attributed to growing trend of administering prophylactic vaccines among the pediatric population.
Cancer Vaccines Market by Region
The global cancer vaccines market can be segmented into North America, Asia Pacific, Europe and Rest of World (ROW). North America dominated the global cancer vaccines market in 2019, owing to factors such as availability of favorable health insurance policies or schemes, high funding & investments for R&D of novel drugs, supportive government regulations, and presence of a large pool of patients suffering from a wide range of cancers among others.
Cancer Vaccines Market Prominent Players
The prominent players operating in the global cancer vaccines market are AstraZeneca, Bavarian Nordics, GlaxoSmithKline, Pfizer Inc., CSL Limited, Sanofi Pasteur, Merck & Co., Inc., Bristol-Myers Squibb, Astellas Pharma Inc., Aduro BioTech, Inc., and Dendreon